Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nyxoah ( (NYXH) ) has issued an announcement.
Nyxoah announced its participation in the 35th Oppenheimer Annual Healthcare MedTech & Services Conference, where CEO Olivier Taelman will present a company update. The company’s involvement in the conference highlights its ongoing efforts to engage with institutional investors and expand its market presence, particularly following positive study results that support its Genio® system’s effectiveness and potential for FDA approval in the U.S.
More about Nyxoah
Nyxoah is a medical technology company focused on developing innovative therapeutic alternatives for obstructive sleep apnea (OSA) through neuromodulation. Their primary product, Genio®, is a battery-free hypoglossal neuromodulation device designed to treat OSA, which has achieved significant clinical success and regulatory approvals in Europe.
YTD Price Performance: 11.06%
Average Trading Volume: 46,166
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $344M
For an in-depth examination of NYXH stock, go to TipRanks’ Stock Analysis page.